COMPANY
Denovo Biopharma
Timeline
- Trial start Phase 2: A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD source ↗
- Trial start Phase 3: A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 source ↗
- Trial start Phase 3: Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ source ↗
- Trial start Phase 1: A Study of LY2140023 in Healthy Participants source ↗
- Trial start Phase 1: A Study of LY2140023 in Healthy Participants source ↗
- Trial start Phase 1: A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia source ↗
- Trial start Phase 1: A Study of LY2140023 in Healthy Participants source ↗
- Trial start Phase 1: A Study of LY2140023 in Healthy Males and Females source ↗
- Trial start Phase 3: A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia source ↗
- Trial start Phase 3: A Physical Dependence Study in Schizophrenia source ↗
- Trial start Phase 1: A Study of LY2140023 in Hepatically-Impaired Participants source ↗
- Trial start Phase 1: The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects source ↗
- Trial start Phase 1: A Study of Safety and Tolerability in Subjects With Schizophrenia source ↗
- Trial start Phase 3: A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients source ↗
- Trial start Phase 3: A Study of LY2140023 in Patients With Schizophrenia source ↗
- Trial start Phase 2/Phase 3: A Long-Term, Open-Label, Study on Schizophrenia source ↗
- Trial start Phase 2: A Study in Schizophrenic Patients source ↗
- Trial start Phase 2: A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients source ↗
- Trial start Phase 2: A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms source ↗
- Trial start Phase 2: A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients source ↗
- Trial start Phase 2: A Study for Participants With Schizophrenia source ↗
- Trial start Phase 2: Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo source ↗
Clinical trials (lead sponsor) 22
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT01440478 | The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects | Phase 1 | Completed | 2011-09 | 2011-10 (actual) |
| NCT00520923 | A Study for Participants With Schizophrenia | Phase 2 | Completed | 2007-09 | 2008-10 (actual) |
| NCT01086748 | A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients | Phase 2 | Completed | 2010-03 | 2012-05 (actual) |
| NCT01129674 | A Long-Term, Open-Label, Study on Schizophrenia | Phase 2/Phase 3 | Terminated | 2010-06 | 2012-10 (actual) |
| NCT01487083 | A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia | Phase 3 | Terminated | 2011-12 | 2012-10 (actual) |
| NCT05113771 | A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD | Phase 2 | Completed | Jun 29, 2022 | Feb 6, 2024 (actual) |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | Phase 3 | Completed | Mar 20, 2018 | Aug 11, 2022 (actual) |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | Phase 3 | Completed | Dec 16, 2020 | Feb 29, 2024 (actual) |
| NCT01606436 | A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia | Phase 1 | Completed | 2012-06 | 2012-08 (actual) |
| NCT00845026 | A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients | Phase 2 | Completed | 2009-03 | 2010-05 (actual) |
| NCT01307800 | A Study of LY2140023 in Patients With Schizophrenia | Phase 3 | Terminated | 2011-03 | 2012-09 (actual) |
| NCT01354353 | A Study of Safety and Tolerability in Subjects With Schizophrenia | Phase 1 | Completed | 2011-05 | 2012-03 (actual) |
| NCT01452919 | A Physical Dependence Study in Schizophrenia | Phase 3 | Completed | 2011-11 | 2012-09 (actual) |
| NCT01328093 | A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients | Phase 3 | Terminated | 2011-04 | 2012-10 (actual) |
| NCT01052103 | A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms | Phase 2 | Completed | 2010-01 | 2012-06 (actual) |
| NCT01475136 | A Study of LY2140023 in Hepatically-Impaired Participants | Phase 1 | Completed | 2011-11 | 2012-12 (actual) |
| NCT01609218 | A Study of LY2140023 in Healthy Participants | Phase 1 | Completed | 2012-06 | 2012-09 (actual) |
| NCT01591330 | A Study of LY2140023 in Healthy Males and Females | Phase 1 | Completed | 2012-04 | 2012-06 (actual) |
| NCT01637142 | A Study of LY2140023 in Healthy Participants | Phase 1 | Completed | 2012-07 | 2012-07 (actual) |
| NCT01125358 | A Study in Schizophrenic Patients | Phase 2 | Terminated | 2010-05 | 2012-09 (actual) |
| NCT01659177 | A Study of LY2140023 in Healthy Participants | Phase 1 | Withdrawn | 2012-08 | 2012-09 (estimated) |
| NCT00149292 | Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo | Phase 2 | Completed | Aug 23, 2005 | Jul 17, 2006 (actual) |